Targeted therapy before surgery for EGFR lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at how well a targeted therapy works before surgery for people with EGFR-mutated non-small cell lung cancer. It aims to understand the link between a heart rhythm measure (RVT) and patient outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have non-small cell lung cancer with an EGFR mutation (a specific genetic change)
- You received targeted therapy before your surgery (neoadjuvant treatment)
- You had surgery to remove the lung tumor (definitive surgery)
- You have not had chemotherapy, immunotherapy, or radiation therapy before
- You have not had cancer or lung surgery in the past and we have all your key medical data
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a targeted therapy pill (EGFR-TKI) can control small spots in the other lung after surgery for early-stage lung cancer. It's for people whose cancer has a specific EGFR gene change and who still have suspicious spots in the opposite lung after one side is removed.
This trial tests giving targeted therapy pills before and after surgery for stage III lung cancer with certain rare gene changes. The goal is to see if this approach helps shrink or control the cancer better than surgery alone.
This trial tests if taking a targeted therapy drug before surgery can help shrink tumors in people with a specific type of lung cancer called EGFR-mutated squamous cell carcinoma that can be removed with surgery. The goal is to see if this approach improves outcomes.
This trial tests two different treatment plans before lung cancer surgery. Both plans start with a targeted pill (limertinib), then one adds immunotherapy plus chemotherapy, and the other adds just chemotherapy. The goal is to see which combination helps shrink the tumor more before surgery.
This trial tests whether giving an immunotherapy drug (toripalimab) before surgery can help people with a specific type of lung cancer (EGFR-mutated, PD-L1 positive) that can be removed. The goal is to see if it improves treatment results compared to surgery alone.
This trial tests a combination of two targeted drugs (firmonertinib and bevacizumab) given before surgery for people with early-stage, EGFR-mutated lung cancer. The goal is to shrink the tumor and improve the chances of successful surgery.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.